Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin

Maisch, Bernhard

doi:10.1053/euhj.2002.3328

Cited by 112 publications

(74 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We and others have reported the low complication rate and the effectiveness of local chemotherapy (Lestuzzi et al, 2000;Maisch et al, 2002;Martinoni et al, 2004;Tomkowski et al, 2004;Bischiniotis et al, 2005). In our personal experience of 139 cases of MPE due to various neoplasms (88 lung cancer) and treated with local chemotherapy (platinum in most cases, given either as single 50 mg in 50 ml of saline in single bolus or as 10 mg in 20 ml of saline over 3 -5 running days), we had no major complications except for: one case of renal failure (treated with fluid and furosemide), one severe chest pain with electrocardiogram abnormalities (but no troponine increase), one atrial fibrillation requiring DC shock for cardioversion and two late constrictive pericarditis after local CT with platinum.…”

Section: Sirmentioning

confidence: 99%

Malignant pericardial effusion: sclerotherapy or local chemotherapy?

et al. 2009

View full text Add to dashboard Cite

Section: Sirmentioning

confidence: 99%

Malignant pericardial effusion: sclerotherapy or local chemotherapy?

et al. 2009

View full text Add to dashboard Cite

“…In a case reported from Japan, cisplatin with gemcitabine, and vinorelbine was shown to provide a 2 year progression-free survival [11]. Intracavitary use of cisplatin, for reducing fluid accumulation, may also prove to be effective [12]. The patient reported here had been diagnosed as having pericardial mesothelioma only after a pericardiectomy and was given a course of carboplatin and pemetrexed, but unfortunately he succumbed to the disease shortly thereafter.…”

Section: Discussionmentioning

confidence: 97%

Primary pericardial malignant mesothelioma: A rare but aggressive disease

Arslan¹

2012

CMJ

View full text Add to dashboard Cite

Malignant mesothelioma of the pericardium is a rare disorder with a worse outcome compared to the pleural presentation of the disease. All treatment modalities are usually palliative. Here we report a patient with malignant mesothelioma of the pericardium presenting with severe dyspnea and pericardial effusion who survived only 2 months despite aggressive treatment. Keywords: Malign mesothelioma, pericardium, chemotherapy ÖzetMalign perikardiyal mezotelyoma plevral mezotelyoma ile karşılaştırıldığında nadir ve daha kötü seyirli bir hastalıktır. Tüm tedavi uygulamaları genellikle palyatif kalmaktadır. Bu makalede ciddi dispne ve perikardiyal effüzyon ile seyreden ve agresif tedaviye rağmen sadece 2 ay yaşayabilen bir malign perikardiyal mezotelyoma olgusu sunulmaktadır. Anahtar sözcükler: Malign mezotelyoma, perikard, kemoterapi Geliş tarihi

show abstract

“…In a register of 42 patients with malignant pericardial effusion, cisplatin administered intrapericardially (30 mg) was less effective in patients with breast cancer in comparison with those with lung cancer. In the 6 months of observation, recurrence of effusion was found in 37.5% of those with breast cancer and in only 4.5% of those with lung cancer, a difference that was statistically significant (23).…”

Section: Management Of the First Episode Of Cardiac Tamponadementioning

confidence: 92%

Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis

Darocha¹,

Wilk²,

Walaszkowska-Czyż³

et al. 2018

View full text Add to dashboard Cite

. Conclusion: Efficacy of rescue intrapericardial chemotherapy with cisplatin is independent of parameters of hemodynamic instability and levels of inflammatory markers in recurrent pericardial effusion.Pericardial diseases constitute an infrequent, although very serious clinical problem among oncological patients. They practically always cause deterioration of the patient's quality of life. The increasing amount of pericardial effusion and the resulting cardiac tamponade is a life-threatening condition which requires urgent diagnostics and treatment.The European Society of Cardiology (ESC) Position Paper related to cardio-oncology summarizes the knowledge on acute and chronic pericarditis as the complication resulting from anticancer treatment: some cytotoxic drugs and radiotherapy (1). Experts indicate that pericardial complications in oncology are usually associated with mediastinal tumors occupying the pericardium. The document does not discuss the issue of pericardial effusion as a potential manifestation of malignant tumor progression. The present state of knowledge concerning malignant pericarditis is based on several retrospective studies and descriptions of small groups of patients. This article presents our own prospective experience related to the treatment of patients suffering from recurrent pericardial effusion and hemodynamic instability in the course of malignant disease.The primary purpose of the observation was the assessment of determinants of overall survival of oncological patients subject to emergency pericardiocentesis and intrapericardial chemotherapy with the use of cisplatin due to recurrent symptomatic pericardial effusion and cardiac tamponade.The detailed aims included the identification of factors which could have direct impact on the overall survival of patients, these included among others: complications of pericardiocentesis and cisplatin administered intrapericardially; signs of inflammatory process: pericardial effusion culture test results, fever, white blood cell count; hemodynamic conditions: baseline level of N-terminal pro-B type natriuretic peptide (NTproBNP), volume and duration of pericardial drainage; interval for recurrence pericardial effusion; possibility of further anticancer treatment. 373

show abstract

Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin

Abstract: Intrapericardial treatment with cisplatin appeared to successfully prevent recurrences of neoplastic pericardial effusion. The treatment was more successful in lung than in breast cancer patients.

Cited by 112 publications

References 35 publications

Malignant pericardial effusion: sclerotherapy or local chemotherapy?

Malignant pericardial effusion: sclerotherapy or local chemotherapy?

Primary pericardial malignant mesothelioma: A rare but aggressive disease

Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis

Contact Info

Product

Resources

About